UBE2N

Across TCGA pan-cancer cohorts, UBE2N Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated UBE2N data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher UBE2N Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2N expression acts as an unfavorable survival marker.

ESCA, STAD, and UCEC are the cancer types where UBE2N Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.108	0.703	<.001	36	view →
STAD	OS	Median	II,III,IV	0.003	0.677	<.001	30	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

UBE2N–ESCA (OS)

Open the ESCA breakdown →